Short peptides. Tissue-specific. Information-bearing.
Bioregulators are the scientific foundation underlying the Opticeutical category. The mechanism-rationale pillar of the standard rests on this body of research.
What a bioregulator is.
Bioregulator peptides are short-chain amino-acid compounds — two to seven residues — that occur naturally in the human body. The institutional research lineage has produced over 800 peer-reviewed publications on these compounds since the 1970s. The Atumnus portfolio holds seven trade-named, patent-pending bioregulator compositions covering the principal regulatory axes of human physiology, formulated under the Opticeutical Standard into consumer products available without a prescription.
The research framework around bioregulators originates primarily from the St. Petersburg Institute of Bioregulation and Gerontology, where investigation has continued across more than four decades. The bioregulator concept is distinct from broader peptide therapeutics in two respects: extreme brevity, and a proposed mechanism of tissue-specific gene-expression modulation rather than surface-receptor binding.
Direct nuclear entry. Tissue-specific expression.
Four sequential events distinguish bioregulator action from conventional pharmacology. Most pharmaceutical interventions stop at the receptor. Bioregulators are proposed to cross it.
Cellular Entry
The defining size — two to seven amino acids — places bioregulators below the threshold at which most peptides require receptor-mediated transport. The published research proposes that bioregulators cross cell membranes and the nuclear envelope without binding to surface receptors, entering the nucleus directly.
Nuclear Interaction
Inside the nucleus, the proposed mechanism involves binding to DNA promoter regions and to histone proteins that organize chromatin. This interaction is proposed to alter chromatin conformation in ways that increase transcriptional accessibility at specific gene loci.
Tissue Specificity
Each bioregulator is designed against a specific tissue. Different chromatin architecture across cell types is proposed to determine which genes become accessible. The same peptide produces different effects in different tissues because the accessible regulatory regions differ.
Epigenetic Modulation
The proposed mechanism is epigenetic rather than genetic. No underlying DNA sequence is altered. The intervention operates on which genes are expressed and at what level — modulation rather than rewriting.
The peptide theory of aging.
A 2002 review published in Neuroendocrinology Lettersproposed that organ-specific regulatory peptides function as information carriers coordinating gene expression within target tissues, and that the age-related decline of these peptides contributes to systemic regulatory deficit. This framework — sometimes called the peptide theory of aging — is the conceptual scaffold for much of the subsequent peptide-class research.
The framework aligns with the broader Hallmarks of Aging schema updated in Cell in 2023, particularly the hallmarks involving epigenetic alteration, intercellular communication disruption, and the accumulation of damaged proteins through glycation and oxidative pathways. Bioregulators are proposed to operate at the intersection of these mechanisms — modulating gene expression patterns that govern protein turnover, glycation response, and tissue-level regulatory tone across the long timescales over which biological aging unfolds.
The discipline that organizes this research framework — formal endogenic pharmacology — is documented in depth at the institutional reference, endogenicpharmacology.com.
Where the science stands.
The bioregulator literature comprises hundreds of published papers across more than four decades. A substantial portion of this work was published in Russian-language journals, which has historically limited Western awareness and independent replication. The body of research is large, internally consistent, and accompanied by extended-duration trials.
The mechanism — direct nuclear entry and DNA interaction by very short peptides — remains an active area of investigation. Some elements are well supported by biochemical and fluorescence-imaging studies; others remain the subject of ongoing replication work. The standard treats bioregulator science as an established research framework, with the qualification that any specific mechanistic claim must be referenceable to published literature.
Why this grounds the Opticeutical category.
The Opticeutical Standard requires that each formulation have an articulated mechanism of action grounded in published science. The bioregulator framework is one of the primary scientific foundations on which products meeting the standard can rest. It supplies a principled answer to the question of how a formulation is supposed to work — at the level of gene expression in a specific tissue — rather than asserting effects without a referenceable mechanism.
For the institutional science in depth, including the full research lineage, the four-layer regenerative model, and the peer-reviewed literature underlying it, the canonical scientific reference is maintained at endogenicpharmacology.com.
endogenicpharmacology.com →